--- schema_version: "secwatch.filing_event.v1" accession: "0001558370-24-006459" form_type: "8-K" ticker: "CBIO" cik: "0001253689" company_name: "CRESCENT BIOPHARMA, INC." filed_at: "2024-05-02T23:59:59+00:00" generated_at: "2026-06-02T23:58:39.601921+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.35 calibrated_materiality_score: 0.35 confidence: "high" source: SEC EDGAR --- # GlycoMimetics stockholders approve increase in authorized shares to 150M and officer exculpation amendment ## Summary - Stockholders voted to increase authorized common stock from 100M to 150M shares (49.3M for, 1.0M against). - Amendment adding Delaware-law officer exculpation provision approved (36.2M for, 1.0M against, 13.2M broker non-votes). - Directors Daniel Junius and Rachel King elected with 34.6M and 37.0M votes for, respectively. - Ratification of Ernst & Young as independent auditor for FY2024 passed with 50.3M votes for. - Advisory vote on executive compensation approved with 35.3M for, 1.9M against. ## SEC filing metadata - accession: 0001558370-24-006459 - form_type: 8-K - ticker: CBIO - cik: 0001253689 - company_name: CRESCENT BIOPHARMA, INC. - filed_at: 2024-05-02T23:59:59+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.35 - calibrated_materiality_score: 0.35 - confidence: high - sec_items: 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/glyc-20240501x8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001558370-24-006459 - JSON: https://secwatch.observer/filing/0001558370-24-006459.json - Plain text: https://secwatch.observer/filing/0001558370-24-006459.txt ## Key facts - Governance Changes CRESCENT BIOPHARMA, INC.: Amendment to certificate of incorporation to add officer exculpation provision as permitted by Delaware law (effective 2024-05-01). - Change: charter amendment - Effective: 2024-05-01 source text: At the 2024 Annual Meeting of Stockholders held on May 1, 2024 (the “ Annual Meeting ”), the stockholders of GlycoMimetics, Inc. (the “ Company ”) approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate ”) to increase the authorized number of shares of the Company’s common stock from 100,000,000 to 150,000,000 shares and (ii) an amendment to the Restated Certificate to include a provision eliminating or limiting monetary liability for specified corporate officers for breach of fiduciary duty in certain actions as permitted by the General Corporation Law of the State of Delaware. evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - Governance Changes CRESCENT BIOPHARMA, INC.: Amendment to increase authorized shares of common stock from 100,000,000 to 150,000,000 shares (effective 2024-05-01). - Change: charter amendment - Effective: 2024-05-01 source text: At the 2024 Annual Meeting of Stockholders held on May 1, 2024 (the “ Annual Meeting ”), the stockholders of GlycoMimetics, Inc. (the “ Company ”) approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate ”) to increase the authorized number of shares of the Company’s common stock from 100,000,000 to 150,000,000 shares and (ii) an amendment to the Restated Certificate to include a provision eliminating or limiting monetary liability for specified corporate officers for breach of fiduciary duty in certain actions as permitted by the General Corporation Law of the State of Delaware. evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - Shareholder Votes CRESCENT BIOPHARMA, INC. shareholders approved Approval, on an advisory basis, of the executive compensation of the named executive officers. at the 2024-05-01 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2024-05-01 source text: Proposal No. 3: Stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The votes were cast as follows: ​ 5,2 Votes For Votes Against Abstentions Approval, on an advisory basis, of the executive compensation of the named executive officers. 35,292,808 ​ 1,881,276 ​ 75,670 ​ Broker Non-Votes: 13,231,353 2 ​ ​ evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - Shareholder Votes CRESCENT BIOPHARMA, INC. shareholders approved Amend Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. at the 2024-05-01 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2024-05-01 source text: Proposal No. 5: Stockholders approved an amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation. The votes were cast as follows: ​ 6,172,8 Votes For Votes Against Abstentions Amend Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. 36,172,684 ​ 1,045,748 ​ 31,322 ​ Broker Non-Votes: 13,231,353 ​ evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - Shareholder Votes CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. at the 2024-05-01 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2024-05-01 source text: Proposal No. 2 : Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: ​ Votes For Votes Against Abstentions Ratification of appointment of Ernst & Young LLP 50,319,444 ​ 40,448 ​ 121,215 ​ ​ ​ evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - Shareholder Votes CRESCENT BIOPHARMA, INC. shareholders approved Amend Certificate of Incorporation to increase authorized shares of common stock from 100,000,000 to 150,000,000. at the 2024-05-01 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2024-05-01 source text: Proposal No. 4: Stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate ”) to increase the authorized number of shares of common stock from 100,000,000 shares to 150,000,000 shares. The votes were cast as follows: ​ Votes For Votes Against Abstentions Amend Certificate of Incorporation to increase authorized shares of common stock from 100,000,000 to 150,000,000. 49,332,242 ​ 1,014,592 ​ 134,273 ​ Broker Non-Votes: 0 ​ evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm - Shareholder Votes CRESCENT BIOPHARMA, INC. shareholders approved Stockholders elected two nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2024-05-01 meeting. - Proposal: director election - Outcome: passed - Meeting: 2024-05-01 source text: Proposal No. 1 : Stockholders elected two nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: ​ Name Votes For Votes Withheld Daniel Junius 34,583,868 ​ 2,665,886 Rachel King ​ 37,007,330 ​ 242,424 ​ ​ Broker Non-Votes: 13,231,353 ​ evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.